Fundings (ICMUB): 180 131 €
Duration: Jan 2025 – 48 months
Scientific leader ICMUB: Franck DENAT (PI of the project)
Descriptif du projet
2in1-ADRC project aims at the development of a new class of therapeutic agents combining advantages of Antibody Drug Conjugates (ADC) and those of Targeted Radiopharmaceuticals (TRP) and compensating for their respective weaknesses, in order to ensure selective delivery of the killing payload at the tumor site while avoiding as much as possible off-target payload release, thus reducing deleterious side effects. A versatile platform will be used for modular conjugation on bispecific biovectors of payloads. Proof of concept of the efficacy of the molecules will be achieved through in vitro and in vivo studies, in the context of two clinically relevant case studies. We expect that the outcomes of this project will pave the way for the design of a next generation of targeted therapeutic agents, with complementary activities on different cell subtypes and tumor settings, resulting in more potent antitumor efficacy than standard ADC or TRP on aggressive or advanced cancers. Beyond this project, the skills and knowledge developed by the partners will be implemented in a broader R&D program to prepare for transfer to the clinic.
Total Fundings: 603 565 €
Partners:
- RADIOMUNE PHARMA
- CRCM Centre de recherche en cancérologie de Marseille